HF
BLCM

HRT Financial’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

HRT Financial’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-36,470
Closed -$26K – 3480
2022
Q4 		$26K Buy
+36,470
New +$36.1K ﹤0.01% 2157

Other funds holding BLCM

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HRT Financial's BLCM Position: Q1 2023 in Review

HRT Financial sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2023, closing a stake of 36,470 shares — an estimated $26K sold.

HRT Financial first reported a position in BLCM in Q4 2022 and held it in 1 quarter. The position peaked at $26K in Q4 2022. 25 funds tracked by Wall St. Rank hold BLCM as of Q1 2023.

  • HRT Financial reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • HRT Financial sold 36,470 Bellicum Pharmaceuticals, Inc. shares in Q1 2023, an estimated $26K.
  • HRT Financial first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2022 and held it in 1 quarter.
  • HRT Financial's Bellicum Pharmaceuticals, Inc. position peaked at $26K in Q4 2022.
  • 25 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2023.

Based on HRT Financial's 13F filing for Q1 2023, filed 12 May 2023.